Research ArticleATOPY

Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis

See allHide authors and affiliations

Science Translational Medicine  26 Feb 2020:
Vol. 12, Issue 532, eaay1005
DOI: 10.1126/scitranslmed.aay1005

Nurturing NK cells to treat atopic dermatitis

The skin condition atopic dermatitis (AD) is driven by a type 2 immune response. Mack et al. performed high-dimensional immune profiling of patients with AD and revealed deficiencies in certain subsets of natural killer (NK) cells. NK cells showed signs of activation-induced cell death and were restored in patients that responded to immunotherapy. Circulating NK cells were also decreased in a mouse AD model; boosting NK cells with an IL-15 superagonist ameliorated symptoms in the mice. These results suggest that strategies to restore NK cells could help rebalance immunity in AD.

View Full Text

Stay Connected to Science Translational Medicine